The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer.
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
24
05
2022
accepted:
09
06
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Short course radiotherapy (SCRT) has a low biological prescription dose. Rectal cancer has a dose response relationship and moderate α/β ratio (∼5). We hypothesise hypofractionated dose escalation has radiobiological advantages. We assessed in-silico dose escalation to the primary tumour using a simultaneous integrated boost (SIB) technique. Patients who had received 25 Gy/5# were enrolled. GTV was macroscopic tumour including lumen. CTVA was GTV + 10 mm. CTVB included elective nodes. PTV_Low was created from CTVF (CTVA + CTVB) + 7 mm. PTV_High (SIB) was GTV + 5 mm margin. OAR were as per RTOG guidelines. Each patient had 4 plans created at increasing dose levels (27.5 Gy, 30 Gy, 32.5 Gy and 35 Gy) to PTV_High. PTV_Low was 25 Gy/5#.5 test plans were created for each patient in Eclipse™ v15.5 and consisted of 2 VMAT full arcs (6 MV), Varian Truebeam (2.7). Planning objectives were set in the Photon optimiser (PO) and recalculated using Acuros v15.5. 20 SCRT patients median age 70, F (n = 5), M (n = 15). Rectum level; low (n = 12), mid (n = 3) and upper (n = 5). 100 plans were analysed. Mean volume of PTV_High was 130 cm Hypofractionated dose escalation to the primary tumour up to 35 Gy/5# is technically feasible in rectal cancer radiotherapy.
Sections du résumé
Background and purpose
UNASSIGNED
Short course radiotherapy (SCRT) has a low biological prescription dose. Rectal cancer has a dose response relationship and moderate α/β ratio (∼5). We hypothesise hypofractionated dose escalation has radiobiological advantages. We assessed in-silico dose escalation to the primary tumour using a simultaneous integrated boost (SIB) technique.
Materials and methods
UNASSIGNED
Patients who had received 25 Gy/5# were enrolled. GTV was macroscopic tumour including lumen. CTVA was GTV + 10 mm. CTVB included elective nodes. PTV_Low was created from CTVF (CTVA + CTVB) + 7 mm. PTV_High (SIB) was GTV + 5 mm margin. OAR were as per RTOG guidelines. Each patient had 4 plans created at increasing dose levels (27.5 Gy, 30 Gy, 32.5 Gy and 35 Gy) to PTV_High. PTV_Low was 25 Gy/5#.5 test plans were created for each patient in Eclipse™ v15.5 and consisted of 2 VMAT full arcs (6 MV), Varian Truebeam (2.7). Planning objectives were set in the Photon optimiser (PO) and recalculated using Acuros v15.5.
Results
UNASSIGNED
20 SCRT patients median age 70, F (n = 5), M (n = 15). Rectum level; low (n = 12), mid (n = 3) and upper (n = 5). 100 plans were analysed. Mean volume of PTV_High was 130 cm
Conclusion
UNASSIGNED
Hypofractionated dose escalation to the primary tumour up to 35 Gy/5# is technically feasible in rectal cancer radiotherapy.
Identifiants
pubmed: 35756193
doi: 10.1016/j.ctro.2022.06.003
pii: S2405-6308(22)00048-9
pmc: PMC9218294
doi:
Types de publication
Journal Article
Langues
eng
Pagination
24-30Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Appl Clin Med Phys. 2016 Nov 08;17(6):78-85
pubmed: 27929483
Clin Colorectal Cancer. 2019 Sep;18(3):209-217
pubmed: 31255477
Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):793-9
pubmed: 17499451
Adv Radiat Oncol. 2018 Aug 06;3(4):611-620
pubmed: 30370362
Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):757-64
pubmed: 26530743
N Engl J Med. 2006 Sep 14;355(11):1114-23
pubmed: 16971718
Radiother Oncol. 2020 Dec;153:67-78
pubmed: 32976873
Lancet Oncol. 2021 Jan;22(1):29-42
pubmed: 33301740
N Engl J Med. 1997 Apr 3;336(14):980-7
pubmed: 9091798
Br J Radiol. 1989 Aug;62(740):679-94
pubmed: 2670032
Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40
pubmed: 28881920
Clin Oncol (R Coll Radiol). 2021 Jan;33(1):e1-e14
pubmed: 32669228
Medicine (Baltimore). 2021 Jan 8;100(1):e24266
pubmed: 33429836
Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8
pubmed: 10802351
Cancer Treat Rev. 2019 Dec;81:101908
pubmed: 31683174
J Clin Oncol. 2012 Nov 1;30(31):3827-33
pubmed: 23008301
Cancer. 2017 Apr 15;123(8):1434-1441
pubmed: 27984651
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e353-62
pubmed: 22483697
Nat Rev Clin Oncol. 2021 Dec;18(12):805-816
pubmed: 34349247
Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):1008-1018
pubmed: 32565319
BMC Health Serv Res. 2015 May 02;15:184
pubmed: 25934169
Radiother Oncol. 2007 Jan;82(1):55-62
pubmed: 17150271
Radiat Oncol. 2019 Jun 24;14(1):113
pubmed: 31234886
BMJ Open. 2019 Mar 23;9(3):e025944
pubmed: 30904869
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e431-8
pubmed: 21669504
Clin Oncol (R Coll Radiol). 2012 May;24(4):261-8
pubmed: 21820294
Lancet Oncol. 2017 Mar;18(3):336-346
pubmed: 28190762
JAMA Netw Open. 2019 Apr 5;2(4):e192249
pubmed: 30977859
Radiother Oncol. 2021 Nov;164:37-42
pubmed: 34534612
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):74-80
pubmed: 22763027
J Clin Oncol. 2006 Oct 1;24(28):4620-5
pubmed: 17008704
N Engl J Med. 2001 Aug 30;345(9):638-46
pubmed: 11547717
Radiother Oncol. 2019 Sep;138:38-44
pubmed: 31136961
Clin Oncol (R Coll Radiol). 2021 Apr;33(4):209-213
pubmed: 33341331
Ann Oncol. 2016 May;27(5):834-42
pubmed: 26884592
BMC Cancer. 2015 Oct 20;15:750
pubmed: 26486986